期刊
VACCINES
卷 9, 期 11, 页码 -出版社
MDPI
DOI: 10.3390/vaccines9111301
关键词
dengue; high-density microarray patch; microneedles; dengue vaccine; chimeric virus; formulation
资金
- National Health and Medical Research Development [APP1139754, APP1178896]
The HD-MAP provides stable delivery of vaccines through dry coating, and HSA has been identified as the leading stabilizing excipient. Vaccines stored on HD-MAP at 4°C for a month maintained vaccine potency and demonstrated high recovery rate.
Alternative delivery systems such as the high-density microarray patch (HD-MAP) are being widely explored due to the variety of benefits they offer over traditional vaccine delivery methods. As vaccines are dry coated onto the HD-MAP, there is a need to ensure the stability of the vaccine in a solid state upon dry down. Other challenges faced are the structural stability during storage as a dried vaccine and during reconstitution upon application into the skin. Using a novel live chimeric virus vaccine candidate, BinJ/DENV2-prME, we explored a panel of pharmaceutical excipients to mitigate vaccine loss during the drying and storage process. This screening identified human serum albumin (HSA) as the lead stabilizing excipient. When bDENV2-coated HD-MAPs were stored at 4 & DEG;C for a month, we found complete retention of vaccine potency as assessed by the generation of potent virus-neutralizing antibody responses in mice. We also demonstrated that HD-MAP wear time did not influence vaccine deposition into the skin or the corresponding immunological outcomes. The final candidate formulation with HSA maintained ~100% percentage recovery after 6 months of storage at 4 & DEG;C.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据